Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation

American Journal of Transplantation

Volumn 11, Issue 11, 2011, Pages 2463-2471

  Gerna, G ^a   Lilleri, D ^a   Chiesa, A ^b   Zelini, P ^b   Furione, M ^b   Comolli, G ^a,b   Pellegrini, C ^c   Sarchi, E ^d   Migotto, C ^e   Regazzi Bonora, M ^f   Meloni, F ^g   Arbustini, E ^a  

^a Laboratori Sperimentali di Ricerca   (Italy)

^b SC Virologia e Microbiologia ^*  (Italy)

^c Divisione di Cardiochirurgia   (Italy)

^d Instituto di Malattie Infettive   (Italy)

^e Sezione di Nefrologia   (Italy)

^f Dipartimento di Farmacologia   (Italy)

^g FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Human cytomegalovirus; Immunologic monitoring; Preemptive therapy; Solid organ transplant recipients; Virologic monitoring

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; EVEROLIMUS; FOSCARNET; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VIRUS DNA;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CARDIAC GRAFT REJECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FLOW CYTOMETRY; FOLLOW UP; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE RECONSTITUTION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; ORGAN TRANSPLANTATION; PATIENT MONITORING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIRAL CLEARANCE; VIRUS DIAGNOSIS; VIRUS REACTIVATION;

ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DENDRITIC CELLS; DNA, VIRAL; FEMALE; FLOW CYTOMETRY; HEART TRANSPLANTATION; HUMANS; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; VIRAL LOAD;

EID: 84857194074     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03636.x     Document Type: Article

References (40)

1. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741-1751. (Pubitemid 28268592)
2. Ljungman P, Griffiths P, Paya C. Definitions of HCMV infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097. (Pubitemid 34289682)
3. Rubin RH. Preemptive therapy in immunocompromised hosts. N Engl J Med 1991; 324: 1057-1059.
4. Kusne S, Shapiro R, Fung J. Prevention and treatment of cytomegalovirus infection in organ transplant recipients. Transpl Infect Dis 1999; 1: 187-203.
5. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-795.
6. Gerna G, Baldanti F, Torsellini M, et al. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: A randomized study. Antivir Ther 2007; 12: 63-72. (Pubitemid 46340427)
7. Rentenaar RJ, Gamadia LE, van der Hoek N, et al. Development of virus-specific CD4(+) T cells during primary cytomegalovirus infection. J Clin Invest 2000; 105: 541-548. (Pubitemid 30127255)
8. Rowshani AT, Bemelman FJ, van Leeuwen EMM, van Lier RAW, ten Berge JM. Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation 2005; 79: 381-386. (Pubitemid 40280168)
9. Radha R, Jordan S, Puliyanda D, et al. Cellular immune responses to cytomegalovirus in renal transplant recipients. Am J Transplant 2005; 5: 110-117. (Pubitemid 40095134)
10. Sester U, Gartner BC,Wilkens H, et al. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant 2005; 5: 1483-1489. (Pubitemid 40839442)
11. Gerna G, Lilleri D, Fornara C, et al. Monitoring of human cytomegalovirus-specific CD4+ and CD8+ T-cell immunity in patients receiving solid organ transplantation. Am J Transplant 2006; 6: 2356-2364. (Pubitemid 44359421)
12. Gerna G, Lilleri D, Rognoni V, et al. Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients. Am J Transplant 2009; 9: 1142-1150.
13. Quinnan GV Jr., Kirmani N, Rook AH, et al. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 1982; 307: 7-13. (Pubitemid 12075446)
14. Waldrop SL, Pitcher CJ, Peterson DM, Maino VC, Picker LJ. Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry. Evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest 1997; 99: 1739-1750. (Pubitemid 27163826)
15. Gratama JW, van Esser JWJ, Lamers CHJ, et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001; 98: 1358-1364.
16. Hebart H, Daginik S, Stevanovic S, et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-c -enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 2002; 99: 3830-3837. (Pubitemid 34534558)
17. Kern F, Faulhaber N, Frommel C, et al. Analysis of CD8+ T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol 2000; 30: 1676-1682. (Pubitemid 30342810)
18. Lilleri D, Zelini P, Fornara C, Comolli G, Gerna G. Inconsistent responses of cytomegalovirus-specific T-cells to pp65 and IE-1 vs infected dendritic cells in organ transplant recipients. Am J Transplant 2007; 7: 1997-2005. (Pubitemid 47038000)
19. Zelini P, Lilleri D, Comolli G, et al. Human cytomegalovirus-specific CD4+ and CD8+ T-cell response determination: Comparison of short-term (24 h) assays vs long-term (7-day) infected dendritic cell assay in the immunocompetent and the immunocompromised host. Clin Immunol 2010; 136: 269-281.
20. Lozza L, Lilleri D, Percivalle E, et al. Simultaneous quantification of human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells by a novel method using monocyte-derived HCMVinfected immature dendritic cells. Eur J Immunol 2005; 35: 1795-1804. (Pubitemid 40862327)
21. Gerna G, Vitulo P, Rovida F, et al. Impact of human metapneumovirus and human cytomegalovirus versus other respiratory viruses on the lower respiratory tract infections of lung transplant recipients. J Med Virol 2006; 78: 408-416. (Pubitemid 43327842)
22. Erratum in: J Med Virol 2008; 80:1869.
23. Lilleri D, Gerna G, and the CMV-Transplant Consensus Working Group. Management of human cytomegalovirus infection in solid organ transplant recipients: Consensus of the Societ á Italiana di Virologia-SIV and the Associazione Microbiologi Clinici-AMCLI. http://www.siv-virologia.it/files/linee guida/ ManagementofHCMVSOTRSIV-AMCLI.pdf. Accessed June 7, 2011.
24. Gerna G, Percivalle E, Lilleri D, et al. Dendritic cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-UL128 genes and mediates efficient viral antigen presentation to CD8+ T cells. J Gen Virol 2005; 86: 275-284. (Pubitemid 40227938)
25. Lilleri D, Baldanti F, Gatti M, et al. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy of human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients. J Med Virol 2004; 73: 412-418. (Pubitemid 38685749)
26. Griffiths P, Whitley R, Snydman DR, Singh N, Boeckh M. Contemporary management of cytomegalovirus infection in transplant recipients: Guidelines from an IHMF workshop, 2007. Herpes 2008; 15: 4-12.
27. Abate D, Saldan A, Fiscon M, et al. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients. J Infect Dis 2010; 202: 585-594.
28. Lilleri D, Lazzarotto T, Ghisetti V, et al. Multicenter quality control study for human cytomegalovirus DNAemia quantification. N Microbiol 2009; 32: 245-253.
29. Avetisyan G, Aschan J, Hägglund H, Ringdén O, Ljungman P. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant 2007; 40: 865-9. (Pubitemid 350020321)
30. Sester M, Sester U, Gärtner B, Girndt M, Meyerhans A, Kohler H. Dominance of virus-specific CD8+ T cells in human primary cytomegalovirus infection. J Am Soc Nephrol 2002; 13: 2577-2584.
31. Sester M, Sester U, Gärtner B, et al. Levels of virus-specific CD4+ T cells correlate with cytomegalovirus control and predict virusinduced disease after renal transplantation. Transplantation 2001; 71: 1287-1294. (Pubitemid 32507149)
32. Gamadia LE, Remmerswaal EBM,Weel JF, Bemelman F, van Lier RAW, Ten Berge IJM. Primary immune responses to human CMV: A critical role for interferon-c -producing CD4+ T cells in protection against CMV disease. Blood 2003; 101: 2686-2692. (Pubitemid 36857631)
33. Gamadia LE, Rentenaar RJ, Baars PA, et al. Differentiation of cytomegalovirus-specific CD8+ T cells in healthy and immunosuppressed virus carriers. Blood 2001; 98: 754-761.
34. Pape L, Offner G, Kreuzer M, et al. De novo therapy with everolimus, low-dose ciclosporine A, basiliximab and steroid elimination in pediatric kidney transplantation. Am J Transplant 2010; 10: 2349-2354.
35. Viganó M, Dengler T, Mattei MF, et al. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: A randomized, multicenter study. Transpl Infect Dis 2010; 12: 23-30.
36. Hill JA, Hummel M, Starling RC, et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 2007; 84: 1436-1442. (Pubitemid 350294718)
37. Westall GP, Michaelidis A, Williams TJ, Snell JI, Kotsimbos TC. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: A longitudinal study of lung quantitative real-time PCR for monitoring clinical intervention in transplant recipients. J Infect Dis 2004; 190: 1076-1083. (Pubitemid 39186793)
38. Bauer CC, Jaksch P, Aberle SW, et al. Relationship between cytomegalovirus DNA load in epithelial lining fluid and plasma of lung transplant recipients and analysis of coinfection with Epstein-Barr virus and human herpesvirus 6 in the lung compartment. J Clin Microbiol 2007; 45: 324-328.
39. Chemaly RF, Yen-Lieberman B, Chapman J, et al. Clinical utility of cytomegalovirus viral load in bronchoalveolar lavage fluid: A longitudinal study in lung transplant recipients. Am J Transplant 2005; 5: 544-548. (Pubitemid 40313346)
40. Riise GC, Andersson R, Bergstrom T, Lundmark A, Nilsson FN, Olofsson S. Quantification of cytomegalovirus DNA in BAL fluid: A longitudinal study in lung transplant recipients. Chest 2000; 118: 1653-1660. (Pubitemid 32001792)